As a first-line hypoglycemic agent for the treatment of type 2 diabetes, MET can activate AMPK to reduce oxidative stress [19] and exert anti-inflammatory effects [20]. This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.